Clinical Trial Update: Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting immunogenicity and safety data for Bio Farma's measles-rubella vaccine in Indonesian infants, bridging Phase 2/3 study (complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Rubella Infection
• Measles

Drugs mentioned

• Measles-Rubella Vaccine (Measles and Rubella vaccine)

Snippet

Sponsor: PT Bio Farma | Conditions: Congenital Rubella Infection, Measles | Phase 2, Phase 3 | Status: COMPLETED